BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22860751)

  • 1. Early and late studies of EMD use in periodontal intrabony defects.
    Mueller VT; Welch K; Bratu DC; Wang HL
    J Periodontal Res; 2013 Feb; 48(1):117-25. PubMed ID: 22860751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of demineralized freeze-dried bone allograft and enamel matrix derivative versus enamel matrix derivative alone for the treatment of periodontal osseous defects in humans.
    Gurinsky BS; Mills MP; Mellonig JT
    J Periodontol; 2004 Oct; 75(10):1309-18. PubMed ID: 15562907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Periodontal regeneration with or without limited orthodontics for the treatment of 2- or 3-wall infrabony defects.
    Ogihara S; Wang HL
    J Periodontol; 2010 Dec; 81(12):1734-42. PubMed ID: 20629545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study utilizing open flap debridement with and without enamel matrix derivative in the treatment of periodontal intrabony defects: a 12-month re-entry study.
    Froum SJ; Weinberg MA; Rosenberg E; Tarnow D
    J Periodontol; 2001 Jan; 72(1):25-34. PubMed ID: 11210070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinical comparison of a bovine-derived xenograft used alone and in combination with enamel matrix derivative for the treatment of periodontal osseous defects in humans.
    Scheyer ET; Velasquez-Plata D; Brunsvold MA; Lasho DJ; Mellonig JT
    J Periodontol; 2002 Apr; 73(4):423-32. PubMed ID: 11990444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of demineralized freeze-dried bone allograft with and without enamel matrix derivative for the treatment of periodontal osseous defects in humans.
    Hoidal MJ; Grimard BA; Mills MP; Schoolfield JD; Mellonig JT; Mealey BL
    J Periodontol; 2008 Dec; 79(12):2273-80. PubMed ID: 19053917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical comparison of an enamel matrix derivative used alone or in combination with a bovine-derived xenograft for the treatment of periodontal osseous defects in humans.
    Velasquez-Plata D; Scheyer ET; Mellonig JT
    J Periodontol; 2002 Apr; 73(4):433-40. PubMed ID: 11990445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of postsurgical antibiotics on the healing of intrabony defects following treatment with enamel matrix proteins.
    Sculean A; Blaes A; Arweiler N; Reich E; Donos N; Brecx M
    J Periodontol; 2001 Feb; 72(2):190-5. PubMed ID: 11288792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year clinical and histologic results following treatment of human intrabony defects with an enamel matrix derivative combined with a natural bone mineral.
    Sculean A; Chiantella GC; Arweiler NB; Becker J; Schwarz F; Stavropoulos A
    Int J Periodontics Restorative Dent; 2008 Apr; 28(2):153-61. PubMed ID: 18546811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healing of two and three wall intrabony periodontal defects following treatment with an enamel matrix derivative combined with autogenous bone.
    Yilmaz S; Cakar G; Yildirim B; Sculean A
    J Clin Periodontol; 2010 Jun; 37(6):544-50. PubMed ID: 20507378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up and tomographic assessment of an intrabony defect treated with enamel matrix derivative.
    Bhatavadekar NB; Paquette DW
    J Periodontol; 2008 Sep; 79(9):1802-8. PubMed ID: 18771385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and histologic evaluation of an enamel matrix derivative combined with a biphasic calcium phosphate for the treatment of human intrabony periodontal defects.
    Sculean A; Windisch P; Szendröi-Kiss D; Horváth A; Rosta P; Becker J; Gera I; Schwarz F
    J Periodontol; 2008 Oct; 79(10):1991-9. PubMed ID: 18834256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enamel matrix proteins and guided tissue regeneration with titanium-reinforced expanded polytetrafluoroethylene membranes in the treatment of infrabony defects: a comparative controlled clinical trial.
    Zucchelli G; Bernardi F; Montebugnoli L; De SM
    J Periodontol; 2002 Jan; 73(1):3-12. PubMed ID: 11846197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes after treatment of non-contained intrabony defects with enamel matrix derivative or guided tissue regeneration: a 12-month randomized controlled clinical trial.
    Siciliano VI; Andreuccetti G; Siciliano AI; Blasi A; Sculean A; Salvi GE
    J Periodontol; 2011 Jan; 82(1):62-71. PubMed ID: 20809859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of enamel matrix proteins and bioabsorbable membranes in the treatment of intrabony periodontal defects. A split-mouth study.
    Sculean A; Donos N; Blaes A; Lauermann M; Reich E; Brecx M
    J Periodontol; 1999 Mar; 70(3):255-62. PubMed ID: 10225541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of an enamel matrix protein derivative combined with a bioactive glass for the treatment of intrabony periodontal defects in humans.
    Sculean A; Barbé G; Chiantella GC; Arweiler NB; Berakdar M; Brecx M
    J Periodontol; 2002 Apr; 73(4):401-8. PubMed ID: 11990441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do bone grafts or barrier membranes provide additional treatment effects for infrabony lesions treated with enamel matrix derivatives? A network meta-analysis of randomized-controlled trials.
    Tu YK; Woolston A; Faggion CM
    J Clin Periodontol; 2010 Jan; 37(1):59-79. PubMed ID: 19958442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enamel matrix derivative versus bioactive ceramic filler in the treatment of intrabony defects: 12-month results.
    Leknes KN; Andersen KM; Bøe OE; Skavland RJ; Albandar JM
    J Periodontol; 2009 Feb; 80(2):219-27. PubMed ID: 19186961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of bioactive glass in the treatment of periodontal defects: a meta-analysis of randomized controlled clinical trials.
    Sohrabi K; Saraiya V; Laage TA; Harris M; Blieden M; Karimbux N
    J Periodontol; 2012 Apr; 83(4):453-64. PubMed ID: 21861641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of pretreatment clinical parameters on bioactive glass implantation in intrabony periodontal defects.
    Park JS; Suh JJ; Choi SH; Moon IS; Cho KS; Kim CK; Chai JK
    J Periodontol; 2001 Jun; 72(6):730-40. PubMed ID: 11453234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.